

BARNES & THORNBURG LLP

11 South Meridian Street
Indianapolis, Indiana 46204
(317) 236-1313
(317) 231-7433 Fax

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Group: 1626

Confirmation No.: 9842

Application No.: 10/725,191

Invention: **PHOSPHORAMIDE
COMPOUNDS**

Applicant: Richard F. Borch et al.

Filed: December 1, 2003

Attorney Docket: 3220-200986

Examiner: Golam M. Shameem

I hereby certify that this correspondence is being
filed electronically in the United States Patent and
Trademark Office

on March 23, 2007


(Signature)

Garla L. Twyman
(Printed Name)

SUBMISSION MADE WITH AN RCE:

Supplemental Information Disclosure Statement

Mail Stop RCE

Commissioner for Patents

P. O. Box 1450

Alexandria, Virginia 22313-1450

Sir:

Applicants have concurrently filed a request for continued examination (RCE) under 37 C.F.R. § 1.114 in a separate paper. In association with that RCE, Applicants hereby request entry and consideration of the instant Submission, which Submission includes a Supplemental Information Disclosure Statement (IDS), Form 1449, and all required copies of the references cited therein.

This IDS is filed in the application identified above pursuant to 37 C.F.R. § 1.56. No representation is intended that a complete search has been made of the prior art or that no better art references than the references cited in the IDS are available. The filing of this IDS shall not be construed to be an admission that the information cited in the IDS is, or


1.98(a)(2)(ii), copies of the cited U.S. patents are not provided herewith. Copies of the cited foreign patent documents and other references (non-patent) have been provided.

The cited references are not believed to disclose or suggest the invention recited in the claims of the above-identified application. It is therefore believed that the claimed invention is patentably distinguishable over the cited references.

Applicants have authorized, concurrent to filing the instant IDS, Barnes & Thornburg LLP Deposit Account 10-0435 to be debited in the amount of \$575.00, which amount is the sum of the \$180.00 fee set forth under 37 C.F.R. 1.17(p) for filing an Information Disclosure Statement, and the \$395.00 fee set forth under 37 C.F.R. § 1.17(e) for requesting continued examination under small-entity status.

Applicants do not believe that any additional fees are due for filing the instant Information Disclosure Statement. However, the Commissioner is hereby authorized to charge any additional fees that may be required, or credit any overpayment, to Barnes & Thornburg LLP Deposit Account No. 10-0435, with reference to our matter number 3220-200986.

Respectfully submitted,
BARNES & THORNBURG LLP



James K. Blodgett
Registration No. 48,480
Agent for Applicants

JKB:glt
Indianapolis, Indiana 46204
317-231-7401

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT				ATTY. DOCKET NO.: 3220-200986 APPLICANT(S): Borch et al. FILING DATE: Dec. 1, 2003		SERIAL NO.: 10/725,191 GROUP: 1626	
--	--	--	--	---	--	---	--

U.S. PATENT DOCUMENTS							
*Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if appropriate
	AA	5,233,031					
	AB	6,903,081					
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
		Document Number	Date	Country	Class	Subclass	Translation Yes No
	AL	WO 93/06120	April 1, 1993	PCT			
	AM	WO 01/74827	Oct. 11, 2001	PCT			
	AN						
	AO						

OTHER REFERENCES <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>		
	AR	"The Synthesis of O-Monosaccharidyl-Methoxycarbonyl-Phosphonamidaes by Arbuzov Reaction," Chen et al., Chinese Chemical Letters, vol. 6, No. 1, pp. 23-26, 1995
	AS	"Design and Synthesis of Lipophilic Phosphoramidate d4T-MP Prodrugs Expressing High Potency Against HIV in Cell Culture: Structural Determinants for <i>in vitro</i> Activity and QSAR," Siseiui, et al., J. Med. Chem. 1999, 42, 4122-4128
	AT	"Phosphoramidates as Potent Prodrugs of Anti-HIV Nucleotides: Studies in the Amino Region," McGuigan et al., Antiviral Chemistry & Chemotherapy (1996) 7(1), 31-36
	AU	"Design and Synthesis of Novel Nucleotide Prodrugs," Meyers et al., American Association for Cancer Research 2000 (Abstract Proof Page), Abstract #100710, dated December 2, 1999
	AV	"Protein Tyrosine Kinases and Cancer," Kolibaba et al., "Biochimica et Biophysica Acta 1333 (1997) F217-F248
	AW	"Receptor Protein-Tyrosine Kinases and Their Signal Transduction Pathways," van der Geer et al., Annu. Rev. Cell Biol., 1994, 10:251-337
	AX	"Src Homology Region 2 Domains Direct Protein-Protein Interactions in Signal Transduction," Moran et al., Proc. Natl. Acad. Sci. USA, Vol. 87, Nov. 1990, pp. 8622-8626
	AY	"Binding of SH2 Domains of Phospholipase C γ 1, GAP, and Src to Activated Growth Factor Receptors," Anderson et al., Science, Vol. 250, Nov. 16, 1990, 979-982
	AZ	"Oncogenes and Signal Transduction," Cantley et al., Cell, Vol. 64, January 25, 1991, 281-302

Examiner	Date Considered
----------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609.
 Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT				ATTY. DOCKET NO.: 3220-200986 APPLICANT(S): Borch et al. FILING DATE: Dec. 1, 2003		SERIAL NO.: 10/725,191 GROUP: 1626	
U.S. PATENT DOCUMENTS							
*Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if appropriate
	BA						
	BB						
	BC						
	BD						
	BE						
	BF						
	BG						
	BH						
	BI						
	BJ						
	BK						
FOREIGN PATENT DOCUMENTS							
		Document Number	Date	Country	Class	Subclass	Translation Yes No
	BL						
	BM						
	BN						
	BO						
OTHER REFERENCES <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>							
	BR	"Recognition and Specificity in Protein Tyrosine Kinase-Mediated Signalling," Songyang et al., TIBS 20, November 1995, 470-475					
	BS	"Targeting Signal Transduction in the Discovery of Antiproliferative Drugs," Saltiel et al., Chemistry & Biology, 1996, Vol. 3, No. 11, 887-893					
	BT	"Peptide Inhibitors of src SH3-SH2-Phosphoprotein Interactions," Gilmer et al., The Journal of Biological Chemistry, Vol. 269, No. 50, December 16, 1994, 31711-31719					
	BU	"Structure-Based Design of a Novel Series of Nonpeptide Ligands That Bind to the pp60 ^{src} SH2 Domain," Lunney et al., J. Am. Chem. Soc. 1997, 119, 12471-12476					
	BV	"Design, Synthesis, and Cocrystal Structure of a Nonpeptide SrcSH2 Domain Ligand," Plummer et al., J. Med. Chem. 1997, 40, 3719-3725					
	BW	"Inhibition of SH2 Domain/Phosphoprotein Association by a Nonhydrolyzable Phosphonopeptide," Domchek et al., Biochemistry 1992, 31, 9865-9870					
	BX	"Nonhydrolyzable Phosphotyrosyl Mimetics for the Preparation of Phosphatase-resistant SH2 Domain Inhibitors," Burke, Jr., et al., Biochemistry, 1994, 33, 6490-6494					
	BY	L-O-(2-Malonyl)tyrosine: A New Phosphotyrosyl Mimetic for the Preparation of Src Homology 2 Domain Inhibitory Peptides," Ye et al., J. Med. Chem. 1995, 38, 4270-7275					
	BZ	"Conformationally Constrained Phosphotyrosyl Mimetics Designed as Monomeric Src Homology 2 Domain Inhibitors," Burke Jr., et al., J. Med. Chem. 1995, 38, 1386-1396					
Examiner						Date Considered	
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

BASED ON FORM PTO 1449

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT				ATTY. DOCKET NO.: 3220-200986 APPLICANT(S): Borch et al. FILING DATE: Dec. 1, 2003		SERIAL NO.: 10/725,191 GROUP: 1626	
U.S. PATENT DOCUMENTS							
*Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if appropriate
	CA						
	CB						
	CC						
	CD						
	CE						
	CF						
	CG						
	CH						
	CI						
	CJ						
	CK						
FOREIGN PATENT DOCUMENTS							
		Document Number	Date	Country	Class	Subclass	Translation Yes No
	CL						
	CM						
	CN						
	CO						
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)							
	CR	"4'-O-[2-(2-Fluoromalonyl)]-L-Tyrosine: A Phosphotyrosyl Mimic for the Preparation of Signal Transduction Inhibitory Peptides," Burke Jr., et al., J. Med. Chem. 1996, 39, 1021-1027					
	CS	"Phosphotyrosine-Containing Dipeptides as High-Affinity Ligands for the p56 ^{lck} SH2 Domain," Llinas-Brunet et al., J. Med. Chem. 1999, 42, 722-729					
	CT	"Acquisition of High-Affinity, SH2-Targeted Ligands via a Spatially Focused Library," Lee et al., J. Med. Chem. 1999, 42, 784-787					
	CU	"Ligands for the Tyrosine Kinase p56 ^{lck} SH2 Domain: Discovery of Potent Dipeptide Derivatives with Monocharged, Nonhydrolyzable Phosphate Replacements," Beaulieu et al., J. Med. Chem. 1999, 42, 1757-1766					
	CV	"Synthesis and Biological Evaluation of 5-Fluoro-2'-Deoxyuridine Phosphoramidate Analogs," Fries et al., J. Med. Chem., 1995, 38, 2672-2680					
	CW	"Synthesis and Biological Activity of Novel 5-Fluoro-2'-Deoxyuridine Phosphoramidate Prodrugs," Meyers et al., J. Med. Chem., 2000, 43, 4313-4318					
	CX	"Synthesis and Evaluation of Nitroheterocyclic Phosphoramidates as Hypoxia-Selective Alkylating Agents," Borch et al., J. Med. Chem., 2000, 43, 2258-2265					
	CY	Gibbs et al., Current Medicinal Chemistry, Vol. 8, No. 12, October 2001, pp. 1437-1465					
	CZ	Borch et al., European Journal of Cancer. Supplement, Pergamon, Oxford, GB, Vol. 2, No. 8, September 2004, p. 176					
Examiner						Date Considered	
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

BASED ON FORM PTO 1449

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT				ATTY. DOCKET NO.: 3220-200986 APPLICANT(S): Borch et al. FILING DATE: Dec. 1, 2003		SERIAL NO.: 10/725,191 GROUP: 1626	
--	--	--	--	---	--	---	--

U.S. PATENT DOCUMENTS							
*Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if appropriate
	DA						
	DB						
	DC						
	DD						
	DE						
	DF						
	DG						
	DH						
	DI						
	DJ						
	DK						

FOREIGN PATENT DOCUMENTS							
		Document Number	Date	Country	Class	Subclass	Translation Yes No
	DL						
	DM						
	DN						
	DO						

OTHER REFERENCES <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>		
	DR	Weidong et al., American Chemical Society. Abstracts of Papers at the National Meeting, ACS, Washington, D.C., Vol. 228, Part 1, 26 August 2004, p. U930
	DS	
	DT	
	DU	
	DV	
	DW	
	DX	
	DY	
	DZ	

Examiner	Date Considered
----------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609.
 Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

BASED ON FORM PTO 1449